Floatz logo

Rep 2139-Mg

Ascites Hepatic

Dormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Ascites Hepatic cohort.

Asset / SponsorPhaseRating
NORMAL HUMAN SERUM ALBUMIN
Anahita Rabiee MD MHS
Phase 4BB
Empagliflozin
Alexandria University
Phase 2/3BB
Fresh Frozen Plasma
Montefiore Medical Center
Phase 4B
GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE)
Noorik Biopharmaceuticals AG
Phase 2B
Dapagliflozin
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 2CCC

View all 11 →

Same molecule, other indications

Rep 2139-Mg is also rated in:

hepatitis D virus infectionDormant
D
Indicative ·
30 / 100
View asset →
cirrhosis of liverDormant
D
Indicative ·
30 / 100
View asset →
esophageal varicesDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →